Incyte Reports Q1 2026 Earnings Results with Revenue Growth and Key Product Performance
Incyte (INCY) reported Q1 2026 earnings with total revenue of $1.27 billion, up 21% year-over-year. Key products like Jakafi and Opzelura showed growth, and the company highlighted regulatory and clinical milestones, including FDA acceptance for a new drug application and positive Phase III trial results.
Tickers: $INCY
Topics: Clinical Data Earnings Report Product Sales Regulatory Milestone Revenue Growth